DAIC

JULY 29, 2024

mtaschetta-millane Mon, 07/29/2024 - 09:16 July 29, 2024 — CorVascular , a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) testing devices, today announced the U.S. Food and Drug Administration (FDA) has cleared its VasoGuard V-Series as Class II medical devices.

Certification 111

Certification Peripheral Arterial Disease Cerebrovascular Disease Quality of Life 111

Science Daily - Heart Disease

APRIL 30, 2024

Atherosclerosis is characterized by a narrowing of arterial walls and can increase risk of coronary artery disease, stroke, peripheral artery disease, or kidney disorders.

Atherosclerosis 59

Atherosclerosis Cancer Peripheral Arterial Disease Coronary Artery Disease 59

Circulation

DECEMBER 14, 2023

Despite the known higher risk of cardiovascular disease in individuals with type 2 diabetes, the pathophysiology and optimal management of diabetic foot ulcers (DFUs), a leading complication associated with diabetes, is complex and continues to evolve. Circulation, Ahead of Print.

Diabetes 76

Diabetes Peripheral Arterial Disease Health Disparities Cardiovascular Disease 76

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 6, 2024

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Patients who had an myocardial infarction, underwent coronary artery bypass graft (hazard ratio, 1.60 [95% CI, 1.55–1.65]),

Coronary Artery Bypass Graft 45

Coronary Artery Bypass Graft Outpatient Peripheral Arterial Disease Cardiovascular Disease 45

Frontiers in Cardiovascular Medicine

JANUARY 21, 2024

Background and aims Epidemiology of atherosclerotic cardiovascular disease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL).

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Coronary Artery Disease Cerebrovascular Disease 45

Open Heart

OCTOBER 17, 2022

Methods A multicentre cross-sectional epidemiological study to estimate the prevalence of elevated Lp(a) in patients with a history of myocardial infarction, ischaemic stroke or peripheral artery disease conducted at 949 sites in 48 countries in North America, Europe, Asia, South America, South Africa and Australia between April 2019 and July 2021.

Cardiovascular Disease 52

Cardiovascular Disease Peripheral Arterial Disease Myocardial Infarction Cholesterol 52

Heart BMJ

MARCH 12, 2024

Objective Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovascular disease (CVD). Eligible and ineligible patients were compared on baseline characteristics, cardiovascular events, major bleeding and mortality.

Cardiovascular Disease 40

Cardiovascular Disease Peripheral Arterial Disease Coronary Artery Disease Myocardial Infarction 40

The British Journal of Cardiology

AUGUST 1, 2024

1 It is associated with an increased risk of atherosclerotic cardiovascular disease, stroke and peripheral arterial disease, independent of traditional cardiovascular risk factors.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Risk Factors Cholesterol Cardiovascular Disease 40

DAIC

MAY 30, 2024

“We are thrilled with the outcome of the PINNACLE I study validating the safety and effectiveness of the LithiX HC IVL in fragmentation of a broad range of moderate to severe vessel calcifications that would elevate PCI treatment for patients with complex cardiovascular disease,” said Motasim Sirhan, Co-founder and CEO of Elixir Medical.

Stents 105

Stents Stent Peripheral Arterial Disease Cardiovascular Disease 105

DAIC

JUNE 18, 2024

patients as soon as possible to elevate the standard of care for cardiovascular disease treatment.” “The “We look forward to working with FDA, Centers for Medicare & Medicaid Services, and respective physician societies to bring this technology t­­o U.S.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

Journal of the American Heart Association

MARCH 27, 2025

Six multimorbidity patterns were identified, including 4 specific patterns: (1) pattern 1, cerebrovascular cluster (histories of cerebrovascular disease and hypertension); (2) pattern 2, traditional cardiovascular disease risk factors cluster (histories of hyperlipidemia, obesity, anddiabetes, and family history of cardiovascular disease and smoking); (..)

Myocardial Infarction 40

Myocardial Infarction Peripheral Arterial Disease Outcomes Chest Pain 40

Circulation

DECEMBER 28, 2023

Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease.

Atherosclerosis 49

Atherosclerosis Peripheral Arterial Disease Coronary Artery Disease Pharmacology 49

The British Journal of Cardiology

AUGUST 1, 2024

Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheral artery disease.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Myocardial Infarction Plaque Cardiovascular Disease 40

DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 26 Similarly, over one-third of ASCVD patients have hsCRP levels above 2 mg/L which indicates a higher risk of heart disease.12,27 4 In the U.S.

Cardiovascular Disease 111

Cardiovascular Disease Heart attacks Heart Attack Coronary Artery Disease 111

DAIC

FEBRUARY 1, 2024

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. per 1,000* - 122.4

Cardiovascular Disease 104

Cardiovascular Disease Atherosclerosis Strokes Stroke 104

Frontiers in Cardiovascular Medicine

JANUARY 14, 2024

Methods This narrative review examines the contemporary literature assessing intermediate- and long-term event rates in patients with established CV disease treated with statins. Repeat revascularization and CV-related death occurs in up to 38% and 33% of patients with peripheral artery disease after three years, respectively.

Peripheral Arterial Disease 64

Peripheral Arterial Disease Cardiovascular Disease Coronary Artery Disease Cerebrovascular Disease 64

DAIC

MAY 1, 2024

These conditions affect millions of individuals across the country each year, with more than 877,500 Americans experiencing symptoms related to heart disease, stroke, or other cardiovascular diseases annually. PAD contributes to 400 amputations each day.

Interventional Cardiology 105

Interventional Cardiology Aortic valve TAVR Peripheral Arterial Disease 105

DAIC

MAY 31, 2024

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104

Journal of the American Heart Association

MARCH 4, 2025

In congenital heart diseases, SDoHs can affect major outcomes, as well. In conclusion, SDoHs significantly impact cardiovascular morbidity and death and specific outcomes of patients with cardiovascular disease.

Cardiovascular Disease 40

Cardiovascular Disease Peripheral Arterial Disease Congenital Heart Disease Coronary Artery Disease 40

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

Introduction Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up.

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Drug Costs Myocardial Infarction 45

Heart BMJ

MARCH 12, 2024

The study aims to evaluate the applicability in the real world of randomised clinical trials (RCT) on antithrombotic treatment in patients with cardiovascular disease (CVD) and peripheral artery disease (PAD).

Peripheral Arterial Disease 52

Peripheral Arterial Disease Myocardial Infarction Heart attacks Heart Attack 52

DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

Frontiers in Cardiovascular Medicine

APRIL 24, 2024

However, HGPS patient-device size mismatch, pervasive peripheral arterial disease, skin and bone abnormalities, and lifelong failure to thrive present unique challenges to intervention. Intervention to relieve critical AS has the potential for immediate improvement in healthspan and lifespan.

Stenosis 52

Stenosis Aortic Peripheral Arterial Disease TAVR 52

Physiologically Speaking

DECEMBER 15, 2023

But resistance training hasn’t been the focus when it comes to improving cardiovascular health and preventing/reversing cardiovascular diseases (CVDs) — that honor goes to aerobic exercise training, for which the cardiovascular benefits are well-established and vast. The answer is yes.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Physiologically Speaking

DECEMBER 15, 2023

But resistance training hasn’t been the focus when it comes to improving cardiovascular health and preventing/reversing cardiovascular diseases (CVDs) — that honor goes to aerobic exercise training, for which the cardiovascular benefits are well-established and vast. The answer is yes.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Cardiometabolic Health Congress

JUNE 29, 2023

“As a women’s cardiovascular health leader specializing in lipidology, I know firsthand that women’s cardiovascular and cardiometabolic care must be approached with unique tools and strategies.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Education Webinar Kidney Disease 40

Open Heart

MARCH 22, 2025

Objective Historical reductions in cardiovascular disease (CVD) due to lifestyle and treatment improvements are now threatened by factors such as increasing obesity and diabetes, but the relative importance of different risk factors varies by CVD condition.

Cardiovascular Disease 52

Cardiovascular Disease Peripheral Arterial Disease Myocardial Infarction Atrial Fibrillation 52

Cardiometabolic Health Congress

DECEMBER 7, 2023

Published on November 30, 2023, in the Journal of the American College of Cardiology, these new guidelines are based on a comprehensive literature review from May 2022 to November 2022, and provide important recommendations to clinicians caring for patients with or at risk of developing cardiovascular disease (CVD).

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Strokes 111

Frontiers in Cardiovascular Medicine

NOVEMBER 25, 2024

Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovascular disease (e.g., stroke), peripheral arterial disease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism.

Cardiovascular Disease 59

Cardiovascular Disease Peripheral Arterial Disease Cerebrovascular Disease Thrombosis 59